XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 12 - Subsequent Events
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Subsequent Events [Text Block]
12.
     Subsequent Events
 
In
April 2018,
NIAID awarded us a Fast Track Phase I/II Small Business Innovative Research (SBIR) grant entitled “
Construction and efficacy testing of novel recombinant vaccine designs for eliciting both broadly neutralizing antibodies and T cells against Lassa virus
.” The initial Phase I grant award is
$299,820
for the project period
April 9, 2018
to
March 
31,
2019.
 
During
April 2018,
we issued
10,000,000
shares of our common stock pursuant to the conversion of
150
shares of our Series D Preferred Stock.